Loading company
Latest annual · FY2025
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (1)
- Net income
- (1)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (0)
- Net income
- (0)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -50.9%
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Yubo International Biotech Ltd (YBGJ) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $12,353 | $3,470 | +256% | 10-K 2026-03-31 · proof |
| Gross profit | $8,165 | $2,648 | +208.3% | 10-K 2026-03-31 · proof |
| Operating income | -$1.2 million | -$1.8 million | 10-K 2026-03-31 · proof | |
| Net income | -$1.1 million | -$1.8 million | 10-K 2026-03-31 · proof | |
| Cash from operating activities | -$842,802 | -$1.3 million | 10-K 2026-03-31 · proof | |
| Total assets | $847,094 | $1.5 million | -44.8% | 10-Q 2026-08-14 · proof |
| Total liabilities | $2.8 million | $4.8 million | -42.2% | 10-K 2026-03-31 · proof |
| Cash and cash equivalents | $8,062 | $7,015 | +14.9% | 10-K 2026-03-31 · proof |
- What was Yubo International Biotech Ltd (YBGJ)'s revenue in fiscal 2025?
- Yubo International Biotech Ltd (YBGJ) reported revenue of $12,353 for fiscal 2025 (the year ended Dec 31, 2025), against $3,470 the year before (+256%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Yubo International Biotech Ltd (YBGJ)'s gross profit in fiscal 2025?
- Yubo International Biotech Ltd (YBGJ) reported gross profit of $8,165 for fiscal 2025 (the year ended Dec 31, 2025), against $2,648 the year before (+208.3%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Yubo International Biotech Ltd (YBGJ)'s operating income in fiscal 2025?
- Yubo International Biotech Ltd (YBGJ) reported operating income of -$1.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$1.8 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Yubo International Biotech Ltd (YBGJ)'s net income in fiscal 2025?
- Yubo International Biotech Ltd (YBGJ) reported net income of -$1.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$1.8 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was Yubo International Biotech Ltd (YBGJ)'s cash from operating activities in fiscal 2025?
- Yubo International Biotech Ltd (YBGJ) reported cash from operating activities of -$842,802 for fiscal 2025 (the year ended Dec 31, 2025), against -$1.3 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are Yubo International Biotech Ltd (YBGJ)'s total assets?
- As of Dec 31, 2025, Yubo International Biotech Ltd (YBGJ) reported total assets of $847,094, against $1.5 million a year earlier (-44.8%). Source: the 10-Q filed with the SEC on Aug 14, 2026 (restated). SEC
- What are Yubo International Biotech Ltd (YBGJ)'s total liabilities?
- As of Dec 31, 2025, Yubo International Biotech Ltd (YBGJ) reported total liabilities of $2.8 million, against $4.8 million a year earlier (-42.2%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are Yubo International Biotech Ltd (YBGJ)'s cash and cash equivalents?
- As of Dec 31, 2025, Yubo International Biotech Ltd (YBGJ) reported cash and cash equivalents of $8,062, against $7,015 a year earlier (+14.9%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:YBGJ&period_type=annual&limit=5"Information only, not investment advice.